Kumaraguru Raja
Stock Analyst at Brookline Capital
(0)
# 5005
Out of 5,270 analysts
19
Total ratings
18.18%
Success rate
-37.29%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Quince Therapeutics | Initiates Coverage On: Buy | 9 | 1.46 | 516.44% | 1 | Dec 18, 2024 | |
Palisade Bio | Initiates Coverage On: Buy | 38 | 0.81 | 4591.36% | 1 | Nov 20, 2024 | |
SAB Biotherapeutics | Initiates Coverage On: Buy | 8 | 1.56 | 412.82% | 1 | Jun 7, 2024 | |
Forte Biosciences | Initiates Coverage On: Buy | 100 | 7.75 | 1190.32% | 2 | May 30, 2024 | |
Hepion Pharmaceutica... | Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 150 | 0.75 | 19900% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 15 | 3.7 | 305.41% | 1 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 9 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 21 | 2.18 | 863.3% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 15 | n/a | n/a | 1 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 90 | 31.18 | 188.65% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 31 | 0.5 | 6100% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 3360 | 1.15 | 292073.91% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 320 | n/a | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 120 | n/a | n/a | 1 | Mar 25, 2021 |